23003-35-2

Usage

Chemical Properties

White solid

Synthesis Reference(s)

Tetrahedron, 61, p. 4569, 2005 DOI: 10.1016/j.tet.2005.03.008

InChI:InChI=1/C6H6BrNO/c1-4-2-3-5(9)6(7)8-4/h2-3,9H,1H3

Upstream product

• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 109-72-8 n-butyllithium 
• 23003-29-4 2,4-dibromo-3-hydroxy-6-methylpyridine 
• 594-19-4 tert.-butyl lithium 
• 920-36-5 (2-methylpropyl)lithium 

Downstream Products

• 24207-22-5 2-bromo-3-methoxy-6-methyl-pyridine 
• 54232-43-8 6-bromo-5-methoxy-2-pyridinecarboxylic acid 
• 170235-19-5 methyl 2-bromo-3-hydroxy-6-pyridinecarboxylate 
• 170235-18-4 methyl 2-bromo-3-methoxy-6-pyridinecarboxylic acid 
• 178876-92-1 6-Bromo-5-hydroxy-pyridine-2-carboxylic acid 
• 168015-04-1 2-bromo-6-(hydroxymethyl)pyridin-3-ol 
• 1342891-22-8 N-((8-bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)-methyl)benzenamine 
• 1342891-24-0 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)benzenamine 
• 1342891-05-7 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-methoxy-N-phenylbenzenesulfonamide 
• 1342891-23-9 N-((8-bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)-methyl)cyclohexanamine 
• 1342891-25-1 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-cyclohexanamine 
• 1342891-06-8 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-nitro-N-phenylbenzenesulfonamide 
• 1342891-07-9 N-cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-isopropylbenzenesulfonamide 
• 1342891-08-0 N-cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide 

Relevant academic research and scientific papers

Metal-ion sensing europium(III) complexes with bidentate phosphine oxide ligands containing a 2,2′-bipyridine framework

Novel EuIII complexes with bidentate phosphine oxide ligands containing a bipyridine framework, i.e., [3,3′-bis(diphenylphosphoryl)-2, 2′-bipyridine]tris(hexafluoroacetylacetonato)europium(III) ([Eu-(hfa) 3(BIPYPO)]) and [3,3′-bis(diphenylphosphoryl)-6,6′- dimethyl-2,2′-bipyridine]tris(hexafluoroacetylacetonato)europium(III) ([Eu(hfa)3(Me-BIPYPO)]), were synthesized for lanthanide-based sensor materials having high emission quantum yields and effective chemosensing properties. The emission quantum yields of [Eu(hfa)3(BIPYPO)] and [Eu(hfa)3(Me-BIPYPO)] were 71 and 73%, respectively. Metal-ion sensing properties of the EuIII complexes were also studied by measuring the emission spectra of EuIII complexes in the presence of ZnII or CuII ions. The metal-ion sensing and the photophysical properties of luminescent EuIII complexes with a bidentate phosphine oxide containing 2,2′-bipyridine framework are demonstrated for the first time.

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

COMPOSITIONS AND USES OF AMIDINE DERIVATIVES

Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.

DI-MACROCYCLES

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combinatio

PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)

A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammato

NOVEL COMPOUNDS

A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammat

INHIBITORS OF HIF AND ANGIOGENESIS

Inhibitors of the Hypoxia Inducible Factor (HIF) and angiogenesis and their methods of use including the treatment of cancer, hypoxia related pathologies, disorders leading to ischemia, for example stroke and ischemic heart disease, and non-cancerous angiogenic diseases are provided.